ASCO 2019 Adding ribociclib to firstline endocrine therapy significantly improves survival for premenopausal women with advanced breast cancer

ASCO 2019: Adding ribociclib to first-line endocrine therapy significantly improves survival for pre-menopausal women with advanced breast cancer

09:38 EDT 1 Jun 2019 | ecancermedicalscience

The international, randomised phase III MONALEESA-7 trial found that adding ribociclib to standard-of-care endocrine therapy significantly improved overall survival for premenopausal women with advanced HR-positive/HER2-negative breast cancer compared...

More From BioPortfolio on "ASCO 2019: Adding ribociclib to first-line endocrine therapy significantly improves survival for pre-menopausal women with advanced breast cancer"